Direct pharmacy access to EC does not increase use
The ability to obtain emergency contraception (EC) directly from a pharmacist does not mean women would be more inclined to use it than if they only had access through a clinic, according to a randomized, controlled trial of over 2,000 women.
The ability to obtain emergency contraception (EC) directly from a pharmacist does not mean women would be more inclined to use it than if they only had access through a clinic, according to a randomized, controlled trial of over 2,000 women.
The participants, who were between 15 and 24 years of age, were assigned to one of three groups: pharmacy access to EC; advance provision of three packs of levonorgestrel EC, or clinic access (control).
The researchers found that the women with pharmacy access were no more likely to use EC than controls (24.2% vs. 21.0%, respectively; P=0.25), while the women in the advance provision group were almost twice as likely to do so (37.4% vs. 21.0%, respectively; P<0.001), even though the frequency of unprotected intercourse was similar (39.8% vs. 41.0%, respectively, P=0.46) between the groups.
Raine TR, Harper CC, Rocca CH, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA. 2005;293:54-62.
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
